Merck & Co, Inc,, West Point, PA 19486, USA.
Allergy Asthma Clin Immunol. 2013 Aug 7;9(1):27. doi: 10.1186/1710-1492-9-27.
Oral corticosteroid prescriptions are often used in clinical studies as an indicator of asthma exacerbations. However, there is rarely the ability to link a prescription to its associated diagnosis. The objective of this study was to characterize patterns of oral corticosteroid prescription orders for asthma patients using an electronic health record database, which links each prescription order to the diagnosis assigned at the time the order was placed.
This was a retrospective cohort study of the electronic health records of asthma patients enrolled in the Geisinger Health System from January 1, 2001 to August 23, 2010. Eligible patients were 12-85 years old, had a primary care physician in the Geisinger Health System, and had asthma. Each oral corticosteroid order was classified as being prescribed for an asthma-related or non-asthma-related condition based on the associated diagnosis. Asthma-related oral corticosteroid use was classified as either chronic or acute. In patient-level analyses, we determined the number of asthma patients with asthma-related and non-asthma-related prescription orders and the number of patients with acute versus chronic use. Prescription-level analyses ascertained the percentages of oral corticosteroid prescription orders that were for asthma-related and non-asthma-related conditions.
Among the 21,199 asthma patients identified in the electronic health record database, 15,017 (70.8%) had an oral corticosteroid prescription order. Many patients (N = 6,827; 45.5%) had prescription orders for both asthma-related and non-asthma-related conditions, but some had prescription orders exclusively for asthma-related (N = 3,450; 23.0%) or non-asthma-related conditions (N = 4,740; 31.6%). Among the patients receiving a prescription order, most (87.5%) could be classified as acute users. A total of 60,355 oral corticosteroid prescription orders were placed for the asthma patients in this study-31,397 (52.0%) for non-asthma-related conditions, 24,487 (40.6%) for asthma-related conditions, and 4,471 (7.4%) for both asthma-related and non-asthma-related conditions.
Oral corticosteroid prescriptions for asthma patients are frequently ordered for conditions unrelated to asthma. A prescription for oral corticosteroids may be an unreliable marker of asthma exacerbations in retrospective studies utilizing administrative claims data. Investigators should consider co-morbid conditions for which oral corticosteroid use may also be indicated and/or different criteria for assessing oral corticosteroid use for asthma.
在临床研究中,口服皮质类固醇处方常被用作哮喘加重的指标。然而,很少有能力将处方与相关诊断联系起来。本研究的目的是使用电子健康记录数据库描述哮喘患者口服皮质类固醇处方的模式,该数据库将每个处方与下达该处方时分配的诊断联系起来。
这是一项对 2001 年 1 月 1 日至 2010 年 8 月 23 日期间参加 Geisinger 健康系统的哮喘患者的电子健康记录进行的回顾性队列研究。合格的患者年龄在 12-85 岁之间,有一名在 Geisinger 健康系统的初级保健医生,并且患有哮喘。根据相关诊断,将每个口服皮质类固醇处方分为与哮喘相关或非哮喘相关的情况。根据哮喘相关口服皮质类固醇的使用情况将其分为慢性或急性。在患者水平的分析中,我们确定了有哮喘相关和非哮喘相关处方的哮喘患者数量,以及急性和慢性使用的患者数量。处方水平的分析确定了与哮喘相关和非哮喘相关情况的口服皮质类固醇处方的百分比。
在电子健康记录数据库中确定的 21199 例哮喘患者中,有 15017 例(70.8%)有口服皮质类固醇处方。许多患者(N=6827;45.5%)有与哮喘相关和非哮喘相关疾病的处方,但有些患者仅开具与哮喘相关(N=3450;23.0%)或非哮喘相关疾病的处方(N=4740;31.6%)。在接受处方的患者中,大多数(87.5%)可归类为急性使用者。本研究共为哮喘患者开出了 60355 张口服皮质类固醇处方-31397 张(52.0%)用于非哮喘相关疾病,24487 张(40.6%)用于哮喘相关疾病,4471 张(7.4%)用于哮喘相关和非哮喘相关疾病。
哮喘患者的口服皮质类固醇处方经常用于与哮喘无关的疾病。在利用行政索赔数据进行回顾性研究时,口服皮质类固醇的处方可能不是哮喘加重的可靠指标。研究人员应考虑可能也需要口服皮质类固醇治疗的合并症,以及评估哮喘患者使用口服皮质类固醇的不同标准。